InvestorsHub Logo
Followers 278
Posts 36868
Boards Moderated 2
Alias Born 04/05/2012

Re: Volcano post# 644887

Thursday, 05/23/2024 3:41:10 PM

Thursday, May 23, 2024 3:41:10 PM

Post# of 651887
Cing .82 adhd pill phase 3 complete / partnership / licensing news watch

Heres a picture of Adhd PILL->. https://ibb.co/LhgT9XV


FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
May 21, 2024 09:00 ET

We are pleased with the FDA’s guidance and perspective regarding our pathway to a timely NDA filing, and we will proceed to complete all remaining requirements accordingly,” said Cingulate Chairman and CEO Shane J. Schaffer. “We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad. Now that we have a clear path to submission, we look forward to engaging with key payer stakeholders to achieve maximum access and market penetration to benefit ADHD patients and their families.”


Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.